Monte Rosa Therapeutics

Monte Rosa spent October exploring and celebrating diversity during Global Diversity Awareness Month. We delved deeper into the challenges within our local communities, deepened our understanding of diversity in clinical trials, shared the richness of our family traditions, and connected through our diverse backgrounds and the experiences that continue to enrich our work every day. #diversity #globaldiversityawarenessmonth

Excellent explainer from Julia Bauman on our paper, “Mining the Cereblon Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition.” This work showcases our bold approach to tackling previously undruggable targets with molecular glue degraders. Thank you, Julia, for your sharp and insightful review! https://bit.ly/3AMgpnf

Join our CEO, Markus Warmuth, for a fireside chat today at Jefferies London Healthcare Conference. View the live webcast here: https://bit.ly/48MtR7a #JefferiesHealthcare

Today, CEO Markus Warmuth will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference in Boston. Tune in to the live webcast: https://bit.ly/3YXVu9Y

Today we share our third quarter 2024 financial results and corporate update. View the full press release here: https://bit.ly/48DdqtI

ICYMI: Our team was on the ground for this week’s 7th TPD and Induced Proximity Summit.   From groundbreaking research to insightful scientific exchange, we are energized by the innovation in our field and the potential to drive meaningful change for patients.   View our team’s presentations to learn more about Monte Rosa’s work on CDK2 and Cyclin E1 molecular glue degraders as well as our programs in GSPT1 and VAV1. https://bit.ly/4e9onEk

Interested in Monte Rosa’s molecular glue degraders for oncology and autoimmune diseases?   Chief Medical Officer Filip Janku presents on how we’re taking MGDs from the bench to the clinic at the 7th TPD and Induced Proximity Summit. https://bit.ly/3YG1m7v

Attending the 7th TPD and Induced Proximity Summit in Boston?     Nina Ilic-Widlund, Director of Oncology Biology, shares how we’re working to accelerate the rational discovery and design of molecular glue degraders, including CDK2 and Cyclin E1 MGDs. Join us to learn more! https://bit.ly/3YG1m7v

This week’s announcement of a global license agreement with Novartis is expected to accelerate and broaden the scope of clinical development of MRT-6160 for immune-mediated diseases, while retaining substantial value for Monte Rosa. We believe it will strengthen our financial position, extend our operational runway, and allow us to advance our pipeline toward key milestones and anticipated proof-of-concept readouts. CEO Markus Warmuth comments on the significance of the agreement: https://bit.ly/3YDsioB

We are so pleased to announce this agreement with Novartis, a key player in immune-mediated conditions, and we are excited about the transformative potential it provides for MRT-6160.